The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient ...

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment ...

According to a review of hospital-based cross-sectional studies, almost half the type 2 diabetes population is micronutrient ...

The pause has raised concerns among health officials and state leaders, as the vague wording leaves billions in Medicaid ...

Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 ...

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.